Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing OncLive®, Oncology Nursing News®, and Medical World News®. Gina joined the company in 2015 and has held various positions on OncLive and Oncology Nursing News. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
Off-the-Shelf CAR T-Cell Product CTX100 Promising in Relapsed/Refractory CD19+ B-Cell Malignancies
October 26th 2020The investigational wholly-owned allogeneic chimeric antigen receptor T-cell therapy CTX110 demonstrated dose-dependent efficacy and responses in patients with relapsed/refractory CD19-positive B-cell malignancies.
Investigational CAR T-Cell Product Plus Immunotherapy Is Active in DLBCL
September 26th 2020The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
High-Risk Biology Associated With Poorer Outcomes in MCL
September 20th 2020Patients with mantle cell lymphoma (MCL) who have high-risk biology, including blastoid variant, a Ki-67 score of at least 30%, or high p53 expression, had a significantly shorter failure-free and overall survival (OS), according to results of a retrospective trial.